Skip to main content
Top
Published in: Thrombosis Journal 1/2013

Open Access 01-12-2013 | Original clinical investigation

Activated protein C resistance in Behcet’s disease

Authors: Hoda Abdel Badaee, Amr Edrees, Sherif Amin, Maher El Amir, Gaafar Ragab

Published in: Thrombosis Journal | Issue 1/2013

Login to get access

Abstract

Behcet’s disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most frequent. Endothelial dysfunction resulting from vascular inflammation is considered to be an important factor of thrombosis, although the endothelial injury itself cannot completely explain the hypercoagulable state of the disease because other vasculitis syndromes do not increase the risk of thrombosis. The aim of this study is to evaluate the prevalence of activated protein C resistance (APC-R) in Egyptian patients with Behcet’s disease. Also, to detect hyperhomocysteinemia in selected cases (with vascular complications) to assess their relationship with thromboembolic complications. The APC resistance ratio mean in the group of patients with vascular involvement was 2.6 ± 0.8 which was less than the group with no vascular involvement 2.8 ± 0.6, with non- significant P-value (0.5). There was more incidence of ocular lesions in the group of patients with high homocysteine level than the group of patients with normal homocytsteine level with significant P-value (0.08).
Literature
1.
go back to reference Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al.: Vascular involvement in Behcet’s disease. J Rheumatol 1992, 19: 402-410.PubMed Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al.: Vascular involvement in Behcet’s disease. J Rheumatol 1992, 19: 402-410.PubMed
2.
go back to reference Gül A, Aslantas AB, Tekinay T, Koniçe M, Ozçelik T: Procoagulant mutations and venous thrombosis in Behçet’s disease. Rheumatology 1999, 38(12):1298-1299.CrossRefPubMed Gül A, Aslantas AB, Tekinay T, Koniçe M, Ozçelik T: Procoagulant mutations and venous thrombosis in Behçet’s disease. Rheumatology 1999, 38(12):1298-1299.CrossRefPubMed
3.
go back to reference Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB, Choi SW, Song YW: Coagulation parameters and plasma total homocysteine levels in Behcet’s disease. Thromb Res 2002, 106: 19-24.CrossRefPubMed Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB, Choi SW, Song YW: Coagulation parameters and plasma total homocysteine levels in Behcet’s disease. Thromb Res 2002, 106: 19-24.CrossRefPubMed
4.
go back to reference Hull RG, Harris EN, Gharavi AE, Tincani A, Asherson RA, Valesini G, Denman AM, Froude G, Hughes GR: Anticardiolipin antibodies: occurrence in Behçet’s syndrome. Ann Rheum Dis 1984, 43(5):746-748.PubMedCentralCrossRefPubMed Hull RG, Harris EN, Gharavi AE, Tincani A, Asherson RA, Valesini G, Denman AM, Froude G, Hughes GR: Anticardiolipin antibodies: occurrence in Behçet’s syndrome. Ann Rheum Dis 1984, 43(5):746-748.PubMedCentralCrossRefPubMed
5.
go back to reference Chafa O, Fischer AM, Meriane F, Chellali T, Sternberg C, Otmani F, Benabadji M: Behçet’s syndrome associated with protein S deficiency. Thrombosis and Hemostasis 1992, 67(1):1-3. Chafa O, Fischer AM, Meriane F, Chellali T, Sternberg C, Otmani F, Benabadji M: Behçet’s syndrome associated with protein S deficiency. Thrombosis and Hemostasis 1992, 67(1):1-3.
6.
go back to reference Guermazi S, Hamza M, Dellagi K: Protein S deficiency and antibodies to protein S in patients with Behcet’s disease. Thromb Res 1997, 86(3):197-204.CrossRefPubMed Guermazi S, Hamza M, Dellagi K: Protein S deficiency and antibodies to protein S in patients with Behcet’s disease. Thromb Res 1997, 86(3):197-204.CrossRefPubMed
7.
go back to reference Caramaschi P, Poli G, Bonora A, Volpe A, Tinazzi I, Pieropan S, Bambara LM, Biasi D: A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine 2010, 77(4):330-334.CrossRefPubMed Caramaschi P, Poli G, Bonora A, Volpe A, Tinazzi I, Pieropan S, Bambara LM, Biasi D: A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine 2010, 77(4):330-334.CrossRefPubMed
8.
go back to reference Mader R, Ziv M, Adawi M, Mader R, Lavia I: Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet’s disease. J Rheumatol 1999, 26: 2404-2408.PubMed Mader R, Ziv M, Adawi M, Mader R, Lavia I: Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet’s disease. J Rheumatol 1999, 26: 2404-2408.PubMed
9.
go back to reference Lenk N, Ozet G, Alli N, Coban O, Erbasi S: Protein C and protein S activities in Behcet’s disease as a risk factors of thrombosis. Int J Dermatol 1998, 37: 124-125.CrossRefPubMed Lenk N, Ozet G, Alli N, Coban O, Erbasi S: Protein C and protein S activities in Behcet’s disease as a risk factors of thrombosis. Int J Dermatol 1998, 37: 124-125.CrossRefPubMed
10.
go back to reference Espinosa G, Font J, Tàssies D, Vidaller A, Deulofeu R, López-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC: Vascular involvement in Behçet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002, 112: 37-43.CrossRefPubMed Espinosa G, Font J, Tàssies D, Vidaller A, Deulofeu R, López-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC: Vascular involvement in Behçet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002, 112: 37-43.CrossRefPubMed
11.
go back to reference Sarican T, Ayabakan H, Turkmen S, et al.: Homocysteine: an activity marker in Behcet’s disease. J Dermatol Sci 2007, 45: 121-126.CrossRefPubMed Sarican T, Ayabakan H, Turkmen S, et al.: Homocysteine: an activity marker in Behcet’s disease. J Dermatol Sci 2007, 45: 121-126.CrossRefPubMed
12.
go back to reference Ozkan Y, Yardim-Akaydin S, Sepici A, et al.: Assessment of homocysteine and nitric oxide levels in Behcet’s disease. Clin Chem Lab Med 2007, 45: 73-77.CrossRefPubMed Ozkan Y, Yardim-Akaydin S, Sepici A, et al.: Assessment of homocysteine and nitric oxide levels in Behcet’s disease. Clin Chem Lab Med 2007, 45: 73-77.CrossRefPubMed
13.
go back to reference International Study Group Criteria: Lancet. 1990, 335(8697):1078-1080. International Study Group Criteria: Lancet. 1990, 335(8697):1078-1080.
14.
go back to reference Gurgey A, Balta G, Boyvat A: Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet’s disease. Blood Coagul Fibrinolysis 2003, 14(2):121-124.CrossRefPubMed Gurgey A, Balta G, Boyvat A: Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet’s disease. Blood Coagul Fibrinolysis 2003, 14(2):121-124.CrossRefPubMed
15.
go back to reference Mammo L, Al-Dalaan A, Bahabri SS, Saour JN: Association of factor V Leiden with Behcet’s disease. J Rheumatol 1997, 24: 2196-2198.PubMed Mammo L, Al-Dalaan A, Bahabri SS, Saour JN: Association of factor V Leiden with Behcet’s disease. J Rheumatol 1997, 24: 2196-2198.PubMed
16.
go back to reference Navarro S, Ricart JM, Medina P, et al.: Activated protein C levels in Behcet’s disease and risk of venous thrombosis. Br J Haematol 2004, 126(4):550-556.CrossRefPubMed Navarro S, Ricart JM, Medina P, et al.: Activated protein C levels in Behcet’s disease and risk of venous thrombosis. Br J Haematol 2004, 126(4):550-556.CrossRefPubMed
17.
go back to reference Toydemir PB, Elhan AH, Tukun A, et al.: Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behcet’s disease. J Rheumatol 2002, 27: 2849-2854. Toydemir PB, Elhan AH, Tukun A, et al.: Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombogenesis in Behcet’s disease. J Rheumatol 2002, 27: 2849-2854.
18.
go back to reference Verity DH, Vaughan RW, Madanat W, et al.: Factor V Leiden mutation is associated with ocular involvement in Behcet’s disease. Am J Ophthalmol 1999, 128: 352-356.CrossRefPubMed Verity DH, Vaughan RW, Madanat W, et al.: Factor V Leiden mutation is associated with ocular involvement in Behcet’s disease. Am J Ophthalmol 1999, 128: 352-356.CrossRefPubMed
19.
go back to reference Silingardi M, Salvarani C, Boiardi L, et al.: Facror V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet’s disease and deep vein thrombosis. Arthritis Rheum 2004, 51(2):177-183.CrossRefPubMed Silingardi M, Salvarani C, Boiardi L, et al.: Facror V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet’s disease and deep vein thrombosis. Arthritis Rheum 2004, 51(2):177-183.CrossRefPubMed
20.
go back to reference Aksu K, Turgan N, Oksel F, et al.: Hyperhomocysteinemia in Behcet’s disease. Rheumatology 2001, 40(6):687-690.CrossRefPubMed Aksu K, Turgan N, Oksel F, et al.: Hyperhomocysteinemia in Behcet’s disease. Rheumatology 2001, 40(6):687-690.CrossRefPubMed
21.
go back to reference Okka M, Oztürk M, Kockar MC, Bavbek N, Rasier Y, Gunduz K: Plasma homocysteine level and uveitis in Behcet’s disease. Isr Med Assoc J 2002, 4(11 Suppl):931-934.PubMed Okka M, Oztürk M, Kockar MC, Bavbek N, Rasier Y, Gunduz K: Plasma homocysteine level and uveitis in Behcet’s disease. Isr Med Assoc J 2002, 4(11 Suppl):931-934.PubMed
22.
go back to reference Hatemi G, Silman A, Bang D, et al.: EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008, 67(12):1656-1662.CrossRefPubMed Hatemi G, Silman A, Bang D, et al.: EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 2008, 67(12):1656-1662.CrossRefPubMed
Metadata
Title
Activated protein C resistance in Behcet’s disease
Authors
Hoda Abdel Badaee
Amr Edrees
Sherif Amin
Maher El Amir
Gaafar Ragab
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2013
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-11-17

Other articles of this Issue 1/2013

Thrombosis Journal 1/2013 Go to the issue